← Leaderboards
Louise Kuhn
Columbia University Health Sciences
$30,488,392
Attributed
$32,220,388
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,187,944 · 16
By mechanism
R01$23,024,806 · 10
U01$5,067,745 · 1
UH3$2,454,490 · 1
UH2$998,103 · 1
U54$967,556 · 1
R21$450,059 · 1
Top collaborators
- Grace M. Aldrovandi5 shared
- Lynette Denny5 shared
- Nomonde Hazel Mbatani2 shared
- Rakiya Saidu Saidu2 shared
- Juanita Olivia Arendse1 shared
- Delivette Castor1 shared
- Rachel C Shelton1 shared
- Parisa Tehranifar1 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Cristiane S Duarte$13,421,746
- Catherine E Monk$19,796,700
- Michael T Yin$11,180,339
- David H Figurski$5,116,622
- Elisa E Konofagou$45,415,693
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseSouth AfricaAntiretroviral TherapyChildClinical TrialsSamplingResourcesCohortWomanMothersInfantMorbidity - Disease RateProgramsClinical ResearchHiv InfectionsAdultLifePharmaceutical PreparationsAnti-Retroviral AgentsSafetyViralPoint Of CareRecruitment ActivityTransmission Process
Grant awards (64)
Strengthening informed consent for authentic participation in perinatal HIV research$119,728
R21 · FY2025 · HD · contact PI
Strengthening informed consent for authentic participation in perinatal HIV research$34,976
R21 · FY2025 · HD · contact PI
Automated Digital Imaging for Cervical Cancer Screening$470,853
R01 · FY2024 · CA · contact PI
Automated Visual Evaluation for Cervical Cancer Screening in HIV-positive Women$323,842
R01 · FY2024 · CA
Strengthening informed consent for authentic participation in perinatal HIV research$295,355
R21 · FY2024 · HD · contact PI
The Empilisweni Center for Women's Health - Advancing Implementation of Equitable Cervical Cancer Control$967,556
U54 · FY2023 · CA
Automated Digital Imaging for Cervical Cancer Screening$516,477
R01 · FY2023 · CA · contact PI
Automated Visual Evaluation for Cervical Cancer Screening in HIV-positive Women$330,097
R01 · FY2023 · CA
Automated Digital Imaging for Cervical Cancer Screening$511,161
R01 · FY2022 · CA · contact PI
Automated Visual Evaluation for Cervical Cancer Screening in HIV-positive Women$335,925
R01 · FY2022 · CA
Oral microbial signatures in perinatal HIV infection$596,588
R01 · FY2021 · DE · contact PI
Automated Digital Imaging for Cervical Cancer Screening$519,004
R01 · FY2021 · CA · contact PI
Automated Visual Evaluation for Cervical Cancer Screening in HIV-positive Women$341,880
R01 · FY2021 · CA
Oral microbial signatures in perinatal HIV infection$616,295
R01 · FY2020 · DE · contact PI
Automated Digital Imaging for Cervical Cancer Screening$555,125
R01 · FY2020 · CA · contact PI
Automated Visual Evaluation for Cervical Cancer Screening in HIV-positive Women$347,008
R01 · FY2020 · CA
Oral microbial signatures in perinatal HIV infection$615,524
R01 · FY2019 · DE · contact PI
Early neonatal treatment and immune quiescence$952,985
U01 · FY2018 · HD · contact PI
Improving specificity of HPV Screen-and-Treat in South Africa$945,771
UH3 · FY2018 · CA · contact PI
Oral microbial signatures in perinatal HIV infection$699,104
R01 · FY2018 · DE · contact PI
Improving specificity of HPV Screen-and-Treat in South Africa$962,232
UH3 · FY2017 · CA · contact PI
Early neonatal treatment and immune quiescence$955,755
U01 · FY2017 · HD · contact PI
Early neonatal treatment and immune quiescence$406,917
U01 · FY2017 · HD · contact PI
Early neonatal treatment and immune quiescence$925,357
U01 · FY2016 · HD · contact PI
Host epigenetic and mitochondrial function in HIV-infected children$686,680
R01 · FY2016 · HD · contact PI
Improving specificity of HPV Screen-and-Treat in South Africa$546,487
UH3 · FY2016 · CA · contact PI
Early neonatal treatment and immune quiescence$887,055
U01 · FY2015 · HD · contact PI
Host epigenetic and mitochondrial function in HIV-infected children$699,164
R01 · FY2015 · HD · contact PI
Improving specificity of HPV Screen-and-Treat in South Africa$498,156
UH2 · FY2015 · CA · contact PI
Early neonatal treatment and immune quiescence$939,676
U01 · FY2014 · HD · contact PI
Host epigenetic and mitochondrial function in HIV-infected children$714,826
R01 · FY2014 · HD · contact PI
Improving specificity of HPV Screen-and-Treat in South Africa$499,947
UH2 · FY2014 · CA · contact PI
Treatment Options for Protease Inhibitor Exposed Children$488,356
R01 · FY2014 · HD · contact PI
Host epigenetic and mitochondrial function in HIV-infected children$711,853
R01 · FY2013 · HD · contact PI
Treatment Options for Protease Inhibitor Exposed Children$476,209
R01 · FY2013 · HD · contact PI
Oral Transmission of HIV through Breastfeeding$275,293
R01 · FY2013 · DE · contact PI
Host epigenetic and mitochondrial function in HIV-infected children$99,541
R01 · FY2013 · HD · contact PI
Host epigenetic and mitochondrial function in HIV-infected children$792,341
R01 · FY2012 · HD · contact PI
Treatment Options for Protease Inhibitor Exposed Children$501,208
R01 · FY2012 · HD · contact PI
Oral Transmission of HIV through Breastfeeding$355,679
R01 · FY2012 · DE · contact PI
Oral Transmission of HIV through Breastfeeding$193,190
R01 · FY2012 · DE · contact PI
Treatment Options for Protease Inhibitor Exposed Children$508,222
R01 · FY2011 · HD · contact PI
Oral Transmission of HIV through Breastfeeding$440,668
R01 · FY2011 · DE · contact PI
Safer Weaning Practices for HIV-infected women$370,812
R01 · FY2011 · HD · contact PI
Treatment Options for Protease Inhibitor Exposed Children$531,284
R01 · FY2010 · HD · contact PI
Treatment Options for Protease Inhibitor Exposed Children$444,690
R01 · FY2010 · HD · contact PI
Oral Transmission of HIV through Breastfeeding$412,462
R01 · FY2010 · DE · contact PI
Safer Weaning Practices for HIV-infected women$386,262
R01 · FY2010 · HD · contact PI
Safer Weaning Practices for HIV-infected women$390,163
R01 · FY2009 · HD · contact PI
Clinical Relevance of Transient Nevirapine Resistance$509,823
R01 · FY2008 · HD · contact PI
Safer Weaning Practices for HIV-infected women$402,487
R01 · FY2008 · HD · contact PI
Clinical Relevance of Transient Nevirapine Resistance$508,075
R01 · FY2007 · HD · contact PI
Safer Weaning Practices for HIV-infected women$413,375
R01 · FY2007 · HD · contact PI
HIV Protective Immunity and Perinatal Exposure$554,707
R01 · FY2006 · HD · contact PI
Clinical Relevance of Transient Nevirapine Resistance$496,670
R01 · FY2006 · HD · contact PI
HIV Protective Immunity and Perinatal Exposure$552,594
R01 · FY2005 · HD
Clinical Relevance of Transient Nevirapine Resistance$513,872
R01 · FY2005 · HD
HIV Protective Immunity and Perinatal Exposure$622,397
R01 · FY2004 · HD
Clinical Relevance of Transient Nevirapine Resistance$524,831
R01 · FY2004 · HD
HIV Protective Immunity and Perinatal Exposure$653,003
R01 · FY2003 · HD
HIV Protective Immunity and Perinatal Exposure$687,174
R01 · FY2002 · HD
EPIDEMIOLOGY OF NEURODEVELOPMENT IN MULTIPLE BIRTHS$96,880
R29 · FY2001 · NS
CELLULAR IMMUNITY TO HIV INFANTS$328,012
R01 · FY2000 · HD
EPIDEMIOLOGY OF NEURODEVELOPMENT IN MULTIPLE BIRTHS$128,305
R29 · FY2000 · NS